# Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility
Canonical URL: https://biopharmsignal.com/news/MESO/mesoblast-draws-us-50m-from-five-year-non-dilutive-facility
Ticker: MESO
Company: Mesoblast
Source: Mesoblast
Published: 2026-06-25 13:46 EST
Original Source URL: https://investorsmedia.mesoblast.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-30 23:56 EST — [Receives FDA BLA Filing Number and Requests Modular Review](https://biopharmsignal.com/news/MESO/receives-fda-bla-filing-number-and-requests-modular-review-03d96298) — Source: Mesoblast
- 2026-06-29 22:13 EST — [Becoming a substantial holder](https://biopharmsignal.com/news/MESO/becoming-a-substantial-holder-3be3e358) — Source: Mesoblast
- 2026-06-28 22:18 EST — [Ceasing to be a substantial holder](https://biopharmsignal.com/news/MESO/ceasing-to-be-a-substantial-holder-aff3eb75) — Source: Mesoblast
- 2026-06-25 13:46 EST — [Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility](https://biopharmsignal.com/news/MESO/mesoblast-draws-us-50m-from-five-year-non-dilutive-facility) — Source: Mesoblast
- 2026-06-25 13:46 EST — [Becoming a substantial holder](https://biopharmsignal.com/news/MESO/becoming-a-substantial-holder) — Source: Mesoblast
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)